Lionco Pharmaceutical Group (603669.SH): Isavuconazonium Sulfate for Injection Obtained Drug Registration Certificate

Lionco Pharmaceutical Group (603669.SH) announced that recently, its wholly-owned subsidiary Hainan Lionco Pharmaceutical Co., Ltd. (hereinafter referred to as "Lionco Pharmaceutical") received the Drug Registration Certificate for Isavuconazonium Sulfate for Injection approved and issued by the National Medical Products Administration (hereinafter referred to as the "NMPA"). The company's acquisition of the Drug Registration Certificate for Isavuconazonium Sulfate for Injection from the NMPA marks that the company has obtained the qualification to manufacture and sell this drug in the domestic market, further enriching the company's anti-infective drug product line and helping to enhance the market competitiveness of the company's products.